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Abstract
Introduction Notch is a family of transmembrane protein
receptors whose activation requires proteolytic cleavage by γ-
secretase. Since aberrant Notch signaling can induce mammary
carcinomas in transgenic mice and high expression levels of
Notch receptors and ligands correlates with overall poor clinical
outcomes, inhibiting γ-secretase with small molecules may be a
promising approach for breast cancer treatment. Consistent
with this hypothesis, two recent papers reported that γ-
secretase inhibitor I (GSI I), Z-LLNle-CHO, is toxic to breast
cancer cells both in vitro and in vivo. In this study, we compared
the activity and cytotoxicity of Z-LLNle-CHO to that of two highly
specific GSIs, DAPT and L-685,458 and three structurally
unrelated proteasome inhibitors, MG132, lactacystin, and
bortezomib in order to study the mechanism underlying the
cytotoxicity of Z-LLNle-CHO in breast cancer cells.
Methods Three estrogen receptor (ER) positive cell lines, MCF-
7, BT474, and T47D, and three ER negative cell lines, SKBR3,
MDA-MB-231, and MDA-MB-468, were used in this study. Both
SKBR3 and BT474 cells also overexpress HER2/neu.
Cytotoxicity was measured by using an MTS cell viability/
proliferation assay. Inhibition of γ-secretase activity was
measured by both immunoblotting and immunofluorescent
microscopy in order to detect active Notch1 intracellular
domain. Proteasome inhibition was determined by using a cell-
based proteasome activity assay kit, by immunoblotting to
detect accumulation of polyubiquitylated protein, and by
immunofluorescent microscopy to detect redistribution of
cellular ubiquitin.
Results We found that blocking γ-secretase activity by DAPT
and L-685,458 had no effect on the survival and proliferation of
a panel of six breast cancer cell lines while Z-LLNle-CHO could
cause cell death even at concentrations that inhibited γ-
secretase activity less efficiently. Furthermore, we observed that
Z-LLNle-CHO could inhibit proteasome activity and the relative
cellular sensitivity of these six breast cancer cell lines to Z-
LLNle-CHO was the same as observed for three proteasome
inhibitors. Finally, we found that the cell killing effect of Z-LLNle-
CHO could be reversed by a chemical that restored the
proteasome activity.
Conclusions We conclude that the cytotoxicity of Z-LLNle-
CHO in breast cancer cells is mediated by proteasome
inhibition, not by γ-secretase inhibition.
Introduction
Notch is a family of single-pass type I transmembrane protein
receptors that, in mammals, includes four homologs, Notch1
to 4 [1]. Ligand-induced Notch receptor activation requires at
least two cleavages that release the intracellular domain from
the cytomembrane and allow it to translocate into the nucleus
where it activates its target genes [1]. The final cleavage is
performed by γ-secretase, whose substrates include all four
Notch receptors and their ligands as well as β-amyloid precur-
sor protein, E-cadherin, CD44, ErbB-4, and ephrin-B1 [2-8].
Aberrant Notch signaling can induce oncogenesis and may
promote the progression of breast cancer. Transgenic mice
overexpressing active Notch1, Notch3, or Notch4 homologs
all developed mammary carcinoma [9,10]. Furthermore, a
recent clinical study reported that the expression level of
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Notch1, Notch3, and JAG-1, one of the Notch ligands, were
inversely correlated with the overall clinical outcomes in breast
cancer patients [11]. These observations have prompted great
interest in targeting Notch signaling in breast cancer for ther-
apeutic benefit. However, it should be noted that Notch2 sig-
naling has been reported to function as a tumor suppressor in
breast cancer cells [12].
Among the several options to block Notch signaling, inhibition
of γ-secretase by small molecules offers a promising approach
and has been used extensively to study the downstream tar-
gets of the Notch signaling pathway [13,14]. However, exper-
imental data supporting the concept that γ-secretase inhibitors
(GSIs) could inhibit the growth of, or kill, breast cancer cells
have been scarce. Two recent reports have provided the
strongest evidence by showing that Z-LLNle-CHO, commonly
considered to be a GSI, has such an effect both in vitro and in
vivo [15,16].
Proteasome inhibitors are a class of recent developed antican-
cer drugs. Z-LLNle-CHO, as a derivative of a widely used pro-
teasome inhibitor MG-132, has been reported to inhibit
chymotryptic protease activity, a core function of the proteas-
ome [17]. In this study, we compared the activity and cytotoxic
effects of Z-LLNle-CHO with those of two other widely used
and highly specific GSIs, DAPT and L-685,458, and with
those of three structurally unrelated proteasome inhibitors,
MG132, lactacystin, and bortezomib. Our results suggest that
the cell killing effect of Z-LLNle-CHO is not mediated by γ-
secretase inhibition, but is mediated by proteasome inhibition.
Materials and methods
Reagents
Z-Leu-Leu-Nle-CHO (Z-LLNle-CHO, also called GSI I), N-(N-
(3,5-Difluorophenacetyl-L-alanyl))-S-phenylglycine  t-Butyl
Ester (commonly called DAPT or GSI IX), (1S-Benzyl-4R-(1-
(1S-carbamoyl-2-phenethylcarbamoyl)-1S-3-methylbutylcar-
bamoyl)-2R-hydroxy-5-phenylpentyl) carbamic acid tert-butyl
ester (commonly called L-685,458 or GSI X), Z-Leu-Leu-Leu-
aldehyde (Z-LLL-CHO, commonly referred to as MG132), lac-
tacystin, and edaravone were purchased from Calbiochem
(San Diego, CA, USA) and dissolved in dimethyl sulfoxide
(DMSO). Bortezomib was purchased from LC Laboratories
(Woburn, MA, USA) and dissolved in DMSO. Tiron was from
Sigma (St. Louis, MO, USA) and dissolved in water.
Cell culture
Three estrogen receptor (ER) positive cell lines, MCF-7, T47D,
and BT474, and three ER negative cell lines, SKBR3, MDA-
MB-231, and MDA-MB-468, were used in this study. Both
SKBR3 and BT474 cells also overexpress HER2/neu. The cul-
ture medium was DMEM/F-12 medium (Gibco, Carlsbad, CA,
USA) supplemented with 10% FBS (Gibco) and GlutaMAX
(Gibco) for all cell lines except SKBR3, which was cultured in
McCoy's 5A medium (Gibco) supplemented with 10% FBS
and GlutaMAX. In addition, MCF-7 culture medium was sup-
plemented with non-essential amino acids (Gibco), sodium
pyruvate (Gibco)and 10 μg/ml of insulin (Sigma). T47D cul-
ture medium was also supplemented with insulin (10 μg/ml).
All cell lines were maintained at 37°C in a humidified atmos-
phere of 5% carbon dioxide in air.
Cell viability and proliferation assay
Cell viability and proliferation was measured using the Cell-
Titer 96® AQueous One Solution Cell Proliferation Assay (MTS)
kit (Promega, Madison, WI, USA). Cells (3000 to 8000 cells/
well) were seeded into 96-well plates in triplicate and allowed
to attach overnight before being treated with increasing con-
centrations of the drugs. All wells, including the control, were
exposed to the same concentration of DMSO to eliminate any
possible effect of the vehicle on cell viability and proliferation.
MTS reagent (20 μl) was added to each well 72 hours later
and, after one to four hours incubation, the absorbance at 490
nm was measured using a microplate reader (FLUOstar
OPTIMA from BMG LABTECH, Offenburg, Germany). Rela-
tive cell viability and proliferation of individual samples was cal-
culated by normalizing their absorbance to that of the
corresponding control sample. The mean and standard devia-
tion (SD) of three independent experiments were used to plot
dose-response curves. The concentrations that kill and/or
inhibit cell growth by 50% (EC50) were calculated from the
equations that best fit the linear range of the dose-response
curves.
Protein sample preparation
Cells at 80% confluence were treated overnight with drugs at
the indicated concentrations and control cultures received
DMSO. The next day, cells were incubated with trypsin/EDTA
(Gibco) solution for 10 minutes before collection by centrifu-
gation. Cell pellets were then washed once with ice-cold PBS,
lysed in lysis buffer (100 mM Tris-HCl (pH 6.8), 10% glycerol,
2% SDS, 1 mM EDTA, 0.002% bromophenol blue, 2 mM NaF,
1 mM Na3VO4, 1 × protease inhibitor cocktail (Roche Applied
Science, Indianapolis, IN, USA)), boiled for five minutes, and
passed through a 21 gauge needle. The positive control sam-
ples were prepared in the same way as the GSI-treated sam-
ples and the negative control samples were prepared by
adding the lysis buffer directly to the culture plates after wash-
ing with PBS without trypsin/EDTA incubation. Protein con-
centrations were quantified using a BCA protein assay
(Pierce, Rockland, IL, USA).
Western blot analysis
Protein samples (50 μg/lane) were separated in 8% SDS-
PAGE gels and transferred to Trans-Blot® pure nitrocellulose
membranes (0.2 μm, Bio-Rad, Hercules, CA, USA). The mem-
b r a n e s  w e r e  b l o c k e d  w i t h  5 %  s k i m  m i l k  i n  T T B S  ( 0 . 1 %
Tween-20, 100 mM Tris-HCl (pH 7.4), 150 mM NaCl) at room
temperature for one hour before being probed overnight at
4°C with primary antibody solution. The primary antibodiesAvailable online http://breast-cancer-research.com/content/11/4/R57
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used were anti-Notch1 (Val1744; Cell Signaling Technology,
Danvers, MA, USA, 1:1000), anti-ubiquitin (clone FK2 from
Millipore, Billerica, MA, USA, 1:1000) and anti-actin (Abcam,
Cambridge, MA, USA, 1:5000). After washing with TTBS four
times for 10 minutes each, the membranes were incubated
with horseradish peroxidase-conjugated anti-rabbit or anti-
mouse (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA, 1:15,000) secondary antibody solution at 4°C for
three hours. After another round of four washes with TTBS, the
membranes were incubated with SuperSignal West Pico
Chemiluminescent Substrate (Pierce), exposed to Fuji (Tokyo,
Japan) film, and then developed to visualize the protein signal.
Construction of flag-tagged Notch1 extracellular 
truncation (N1EXT) vector
Synthetic DNA oligonucleotides corresponding to the cDNA
encoding human Notch1 signal peptide flanked by restriction
enzyme recognition sequences were integrated into pCMV-
Tag4A vector (Stratagene, La Jolla, CA, USA) using Sac II/
BamH I sites. Then the cDNA encoding the amino acid resi-
dues 1721 to 2555 (corresponding to the substrate of γ-
secretase) was amplified using reverse transcription-coupled
PCR of MCF-7 total cellular RNA and integrated into the vec-
tor containing the Notch1 signal peptide-encoding sequence
using BamH I/EcoR I sites. The sequence of the new con-
struct was verified by sequencing using T3/T7 primers.
Transfection and treatment
N1EXT plasmid DNA was transfected into MCF-7 and SKBR3
cells plated on glass coverslips using Lipofectamine 2000 rea-
gent (Invitrogen, Carlsbad, CA, USA). Culture medium was
replaced six hours after transfection with fresh medium con-
taining 5 μM of DAPT, 2 μM of L-685,458, or Z-LLNle-CHO at
the calculated EC50 values of individual cell lines. After over-
night incubation to allow the expression of exogenous protein,
cells were fixed with 4% paraformaldehyde solution for indi-
rect immunofluorescent microscopy.
Indirect immunofluorescent microscopy
Fixed cells were first permeabilized with 0.5% Triton X-100 in
PBS at room temperature for five minutes and then probed
with anti-Flag monoclonal antibody (clone M2 from Sigma,
1:500) at room temperature for one hour. After five washes
with PBS, cells were incubated with Alexa 488-conjugated
goat anti-mouse secondary antibody (Molecular Probes,
Carlsbad, CA, USA, 1:250) at room temperature for 45 min-
utes and further counterstained with 0.5 μg/ml of DAPI after
five washes with PBS. Images were taken using LSM 510
laser scanning confocal microscope with a Plan-Neofluar 40X/
1.3NA oil-immersion objective lens (Carl Zeiss, Jena, Ger-
many). The optical slice thickness was less than 0.9 μm.
Determination of ubiquitin distribution
MCF-7 and MDA-MB-231 cells plated on glass coverslips
were treated with drugs at the indicated concentrations for
four hours before being fixed in 4% paraformaldehyde solu-
tion. Fixed cells were immunostained in the same way as
above except that anti-ubiquitin monoclonal antibody (clone
FK2 from Millipore, 1:1,000) was used as the primary anti-
body. Images were taken using LSM 710 laser scanning con-
focal microscope with a Plan-Apochromat 20X/0.8NA
objective lens (Carl Zeiss). The optical slice thickness was 1.8
μm.
Proteasome activity assay
Proteasome activity was measured using the Proteasome-
Glo™ Chymotrypsin-Like Cell-Based Assay kit (Promega,
Madison, WI, USA). Briefly, MCF-7 (6000 cells/well) and
MDA-MB-231 (104 cells/well) cells were plated into white-
walled 96-well plates. After overnight incubation to allow cell
attachment, cells were treated with drugs at indicated concen-
trations for two hours. Equal volumes of Proteasome-Glo™
reagent were then added and the luminescence signal was
measured using a microplate reader (FLUOstar OPTIMA).
Results
Among the three GSIs, only Z-LLNle-CHO induces cell 
death
We first compared the cytotoxicity of Z-LLNle-CHO to two
other widely used GSIs, DAPT and L-685,458. Treatment with
Z-LLNle-CHO resulted in a dose-dependent decrease in cell
viability/proliferation of all six breast cancer cell lines tested
with ER-negative cell lines being more sensitive than ER-posi-
tive cell lines. The calculated ED50 values were 3.25 μM, 2.5
μM, 2.4 μM, 1.8 μM, 1.6 μM, and 1.4 μM for MCF-7, BT474,
T47D, MDA-MB-231, SKBR3, and MDA-MB-468, respec-
tively. However, DAPT and L-685,458 had no cell killing and/
or growth inhibitory effects at concentrations up to 5 μM and
2 μM, respectively (Figure 1).
All three GSIs inhibit γ-secretase activity
We then examined whether the lack of cell killing/growth inhi-
bition by DAPT and L-685,458 was due to their lower potency
in inhibiting γ-secretase activity. To address this question, we
first performed immunoblot analysis using an antibody that
only recognizes cleaved Notch1 intracellular domain (N1ICD)
[18,19]. As N1ICD is a product of γ-secretase, its abundance
is a good indicator of γ-secretase activity. However, the
endogenous N1ICD level (the negative control lanes in Figure
2a) is too low to be detected confidently. Therefore, we took
advantage of the fact that calcium depletion activates Notch1
in the absence of ligand binding [20]. As shown in Figure 2a,
DAPT at 5 μM and L-685,458 at 2 μM could block calcium
depletion-induced Notch1 cleavage in all six cell lines. At the
same time, Z-LLNle-CHO, at the concentrations that inhibited
cell growth/viability by 50%, failed to do so to a comparable
level in SKBR3 and MDA-MB-468 cells, although similar inhi-
bition was observed in the other four cell lines treated with this
drug.Breast Cancer Research    Vol 11 No 4    Han et al.
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To confirm the potency of DAPT and L-685,458 on inhibiting
γ-secretase activity in intact cells, we transfected MCF-7 and
SKBR3 cells with a plasmid expressing a Flag-tagged N1EXT
fragment that mimics the immediate substrate of γ-secretase
and then treated them with the same concentrations of GSIs
as used for the western blot analysis. Without any intervention,
the exogenous protein will be cleaved by γ-secretase as long
as it is transported to the plasma membrane to produce
N1ICD that can be visualized as nuclear signal when trans-
fected cells are immunostained with an anti-Flag antibody
(control panels in Figure 2b). In contrast, when γ-secretase
activity is inhibited, the exogenous protein cannot be cleaved
and therefore will accumulate at the plasma membrane. As
shown in Figure 2b, all the DAPT- and L-685,458-treated cells
and Z-LLNle-CHO-treated MCF-7 cells showed exclusively
membrane signal. However, 24% and 58% of Z-LLNle-CHO-
treated SKBR3 cells displayed mainly nuclear signal or a mix-
ture of nuclear and plasma membrane signal, respectively. This
is consistent with the immunoblotting data demonstrating that
DAPT and L-685,458 could completely inhibit γ-secretase
activity at tested concentrations in both cell lines but Z-LLNle-
CHO could only do so in MCF-7 cells (Figure 2c).
Taken together, because complete inhibition of γ-secretase
activity by two structurally unrelated GSIs had no effect on cell
viability and proliferation, it is unlikely that the cell killing/
growth inhibitory effect of Z-LLNle-CHO on breast cancer cell
lines was mediated by γ-secretase inhibition.
Z-LLNle-CHO has proteasome inhibitory activity
Z-LLNle-CHO is derived from a widely used proteasome inhib-
itor MG132 (Z-LLL-CHO) and has been reported to be a
broad chymotryptic and aspartyl protease inhibitor [17].
Therefore, we examined whether Z-LLNle-CHO also has pro-
teasome inhibitor activity at the concentrations that showed
dose-dependent cytotoxicity. We first used a cell-based pro-
teasome activity kit to measure proteasome activity after cells
were treated with MG132, Z-LLNle-CHO, or DAPT. As shown
in Figure 3b, both Z-LLNle-CHO and MG132 showed a dose-
dependent inhibition of the proteasome at concentrations that
showed cytotoxic effects, although DAPT did not. Next, we
examined whether or not inhibition of proteasome activity
caused accumulation of polyubiquitinated protein, one of the
major causes of proteasome inhibitor-induced cell death [21],
by subjecting the protein samples from cells treated with 5 μM
Figure 1
Effect of three different GSIs on the viability/proliferation of six breast cancer cell lines Effect of three different GSIs on the viability/proliferation of six breast cancer cell lines. Breast cancer cells were treated with Z-LLNle-CHO, DAPT, 
or L-685,458 for 72 hours before relative cell viability/proliferation was measured by MTS assay. Results represent the mean ± standard deviation of 
three independent experiments. GSI = γ-secretase inhibitor.Available online http://breast-cancer-research.com/content/11/4/R57
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Figure 2
DAPT and L-685,458 inhibit γ-secretase activity DAPT and L-685,458 inhibit γ-secretase activity. (a) Cells were treated overnight with Z-LLNle-CHO at calculated ED50 values, 5 μM of DAPT, or 2 
μM of L-685,458 before protein samples were prepared. Extracellular calcium was depleted by incubation with 0.53 mM of EDTA for 10 minutes to 
activate Notch1 before sample preparation for all samples except the negative controls. Protein samples were then subjected to western blot analy-
sis with an antibody (V1744) that specifically recognizes active Notch1 intracellular domain (product of γ-secretase-mediated cleavage). Stronger 
V1744 signal intensity indicates greater γ-secretase activity. The treatment conditions were (from lane 1 to lane 5): dimethyl sulfoxide (DMSO) vehi-
cle only and without calcium depletion as negative control; DMSO vehicle only and with calcium depletion to activate Notch1 as positive control; Z-
LLNle-CHO at concentrations equal to the IC50 of individual cell lines; DAPT at 5 μM; L-685,458 at 2 μM. (b) MCF-7 (top panels) and SKBR3 (bot-
tom panels) cells were transfected with plasmid DNA expressing a Flag-tagged protein that mimics the immediate substrate of γ-secretase, treated 
overnight with Z-LLNle-CHO at calculated ED50 values, 5 μM of DAPT or 2 μM of L-685,458, and then immunostained with anti-Flag antibody. The 
appearance of nuclear Flag signal indicates the presence of active γ-secretase. Please note the γ-value of Flag signal was enhanced to visualize 
weak nuclear or cytomembrane signal. (c) Protein samples were prepared without calcium depletion from MCF-7 and SKBR3 cells that were trans-
fected and treated in the same way as the cells in panel b and were subjected to immunoblotting with anti-Notch1 (V1744) antibody. The treatment 
conditions were (from lane 1 to lane 4): DMSO vehicle only; DAPT; L-685,458; and Z-LLNle-CHO.Breast Cancer Research    Vol 11 No 4    Han et al.
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(MCF-7) or 2.5 μM (MDA-MB-231) of Z-LLNle-CHO overnight
to immunoblotting with an anti-ubiquitin antibody. We used
bortezomib, a specific proteasome inhibitor that has been
approved to treat multiple myeloma in patients, as the positive
control. The results showed that treatment with Z-LLNle-CHO
indeed resulted in the same accumulation of polyubiquitinated
protein that was observed with bortezomib (lane 2 and 5 of
Figure 3b). Finally, we took advantage of a recent observation
that when proteasome-mediated protein degradation was
inhibited, cellular ubiquitin would undergo a nuclear-to-cyto-
plasmic redistribution that could be detected by anti-ubiquitin
FK2 antibody [22]. In untreated MCF-7 and MDA-MB-231
cells, FK2 staining showed dominant nuclear signal (Figure
3c). After a four hour treatment with either bortezomib or Z-
LLNle-CHO but not with DAPT, cells displayed a strong cyto-
plasmic ubiquitin signal, confirming proteasome activity was
inhibited by Z-LLNle-CHO.
The cellular sensitivity of six breast cancer cell lines to Z-
LLNle-CHO is the same as that to proteasome inhibitors
We next asked whether or not the cell killing effect of Z-LLNle-
CHO is mediated by its proteasome inhibition activity. If this is
Figure 3
Z-LLNle-CHO has a proteasome inhibitory function Z-LLNle-CHO has a proteasome inhibitory function. (a) Proteasome activity in intact cells was directly measured using a cell-based assay after MCF-
7 and MDA-MB-231 cells were treated with indicated drugs for two hours. Results represent the mean ± standard deviation of three independent 
experiments. (b) Protein samples were prepared from MCF-7 and MDA-MB-231 cells that were treated with different combinations of drugs over-
night and were subject to immunoblotting with anti-ubiquitin antibody (clone FK2 from Millipore, 1:1,000). Actin immunoblotting was used as loading 
control. The treatment conditions were (from lane 1 to lane 8): dimethyl sulfoxide (DMSO) vehicle only; Z-LLNle-CHO alone; Z-LLNle-CHO plus 
tiron; Z-LLNle-CHO plus edaravone; bortezomib alone; bortezomib plus tiron; bortezomib plus edaravone; lactacystin. The concentrations of Z-
LLNle-CHO, tiron, edavarone, bortezomib, and lactacystin are 5 μM, 2 mM, 100 μM, 100 nM, 20 μM for MCF-7 cells, and 2.5 μM, 0.5 mM, 100 μM, 
40 nM, 5 μM for MDA-MB-231 cells, respectively. The accumulation of polyubiquitinated proteins is an indicator of proteasome inhibition. (c) MCF-
7 and MDA-MB-231 cells were treated with different combinations of drugs for four hours and then immunostained with anti-ubiquitin FK2 antibody. 
The treatment conditions were (from 1 to 8): DMSO vehicle only; Z-LLNle-CHO alone; Z-LLNle-CHO plus tiron; Z-LLNle-CHO plus edaravone; bort-
ezomib alone; bortezomib plus tiron; bortezomib plus edaravone; DAPT. The concentrations of Z-LLNle-CHO, tiron, edaravone, and bortezomib were 
the same as that were used for preparation of protein samples in subsection b. 5 μM of DAPT was used for both MCF-7 and MDA-MB-231 cells. 
The redistribution of nuclear ubiquitin to cytoplasm is a phenomenon that can be induced by proteasome inhibition.Available online http://breast-cancer-research.com/content/11/4/R57
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the case, the relative cellular sensitivity of different breast can-
cer cell lines to Z-LLNle-CHO should reflect that produced by
other proteasome inhibitors. Therefore, we treated the same
six breast cancer cell lines with increasing doses of three
structurally unrelated proteasome inhibitors, MG132, lacta-
cystin, and bortezomib, and measured the effects on cell via-
bility/proliferation using the MTS assay. Similar to the results
shown in Figure 1, ER-positive cell lines were more resistant
to all the three proteasome inhibitors than ER-negative cell
lines (Figure 4). In addition, our results were also consistent
with a previous study using bortezomib alone [23]. These data
strongly suggest that the cell killing effects of Z-LLNle-CHO in
breast cancer cells is mediated by its proteasome inhibitory
function.
The cytotoxicity of Z-LLNle-CHO can be reversed by a 
specific antioxidant that restores proteasome activity
Recent studies showed that the proteasome inhibitory activity
as well as the cell killing effects of bortezomib and MG132
could be specifically blocked by two antioxidants, tiron and
edaravone, respectively [24,25]. As Z-LLNle-CHO is structur-
ally similar to MG132, we speculated that edaravone might
also be able to reverse the cytotoxicity of Z-LLNle-CHO by
blocking its proteasome inhibition activity. Therefore, we first
treated MCF-7 and MDA-MB-231 cells with different combi-
nations of bortezomib or Z-LLNle-CHO and tiron or edar-
avone, and then measured cell growth using the MTS assay.
Consistent with previous studies, tiron but not edaravone res-
cued cells from bortezomib-induced cell killing. Most impor-
tantly, we found edaravone but not tiron could rescue cells
from Z-LLNle-CHO-induced cell killing (Figure 5a).
Next, we tested whether or not edaravone could rescue pro-
teasome activity from Z-LLNle-CHO-induced inhibition. We
exposed cells to edaravone at the concentration that showed
best cell growth rescue in the presence of Z-LLNle-CHO and
measured proteasome activity using the three approaches we
used above. We used tiron to reverse bortezomib-induced
proteasome inhibition as a control. We found that edaravone
indeed rescued the proteasome activity from Z-LLNle-CHO-
induced, but not bortezomib-induced, inhibition. Although the
proteasome activity of edaravone rescued from Z-LLNle-CHO-
induced inhibition was not to the same extent as tiron rescued
bortezomib-induced inhibition in the cell based proteasome
assay (Figure 5b), the rescued proteasome activity was
enough to prevent the accumulation of polyubiquitinated pro-
teins (lane 4 compared with lane 2 in Figure 3b) and redistri-
bution of cellular ubiquitin (Figure 3c, treatment 4 vs. treatment
2). In addition, we found edaravone also partially restored γ-
secretase activity from Z-LLNle-CHO-induced inhibition (Fig-
ure 5c).
γ-secretase inhibition activity of Z-LLNle-CHO does not 
contribute to its cytotoxicity to breast cancer cells
To investigate whether the cytotoxicity of Z-LLNle-CHO to
breast cancer cells is due to the summation or synergy of its
dual activities, we tested whether a combination of a specific
γ-secretase inhibitor with a specific proteasome inhibitor could
produce an additive or synergetic effect on cell killing. We
subjected cells to increasing concentrations of lactacystin
with or without 5 μM of DAPT that completely inhibited γ-
secretase activity in the cell lines tested. We found the dose-
response curves of individual cell lines treated with or without
DAPT was almost identical (Figure 6), which suggests there
was no additive or synergetic effects of inhibiting both γ-secre-
tase activity and proteasome activity. Therefore, γ-secretase
inhibitory activity of Z-LLNle-CHO most likely does not contrib-
ute to its cell killing effect in breast cancer cells.
Discussion
Blocking Notch signaling by inhibiting γ-secretase activity with
small molecules has been suggested to be a promising
Figure 4
The relative sensitivity of six cell lines to three proteasome inhibitors is the same as that to Z-LLNle-CHO The relative sensitivity of six cell lines to three proteasome inhibitors is the same as that to Z-LLNle-CHO. Cells were treated with MG132, borte-
zomib, or lactacystin at indicated concentrations for 72 hours before cell viability was measured by MTS assay. Results represent the mean ± stand-
ard deviation of three independent experiments. Please note the relative cellular sensitivity of the same six breast cancer cell lines to three structurally 
unrelated proteasome inhibitors was the same as that to Z-LLNle-CHO in Figure 1.Breast Cancer Research    Vol 11 No 4    Han et al.
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approach to battle breast cancer [13,14]. In fact, there are
three ongoing clinical trials registered at ClinicalTrials.gov
using GSIs in the treatment of breast cancer. However, exper-
imental data supporting the effectiveness of GSIs in the inhibi-
tion of cell growth or killing of breast cancer cells have been
scarce. Two recent reports, however, have now shown that Z-
LLNle-CHO, commonly called GSI I, has such an effect both
in vitro and in vivo [15,16].
In the present study, we first compared the cytotoxicity and
activity of Z-LLNle-CHO with two other popularly used GSIs,
DAPT and L-685,458. We found that completely inhibiting γ-
Figure 5
The cytotoxicity effect of Z-LLNle-CHO could be reversed by edaravone that blocks its proteasome inhibitory function The cytotoxicity effect of Z-LLNle-CHO could be reversed by edaravone that blocks its proteasome inhibitory function. (a) Cells were treated with 
indicated drugs for 72 hours before cell growth was measured using MTS assay. Results represent the mean ± standard deviation (SD) of three 
independent experiments. (b) Proteasome activity in intact cells was directly measured using a cell-based assay after cells were treated with differ-
ent combinations of drugs for two hours. The treatment conditions were (from left to right): dimethyl sulfoxide (DMSO) vehicle only; bortezomib 
alone; bortezomib plus tiron; bortezomib plus edaravone; Z-LLNle-CHO alone; Z-LLNle-CHO plus tiron; and Z-LLNle-CHO plus edaravone. The con-
centrations of bortezomib, tiron, edavarone, and Z-LLNle-CHO are 100 nM, 2 mM, 100 μM, and 5 μM for MCF-7 cells, and 40 nM, 0.5 mM, 100 μM, 
and 2.5 μM for MDA-MB-231 cells, respectively. Results represent the mean ± SD of three independent experiments. (c) The same protein samples 
used for immunoblotting in Figure 3b plus another negative control sample were subjected to immunoblotting with anti-Notch1 (V1744) antibody 
that specifically recognizes active Notch1 intracellular domain. The order of the samples were the same as that in Figure 3b except that lane 1 is the 
new negative control sample.Available online http://breast-cancer-research.com/content/11/4/R57
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secretase activity by DAPT and L-685,458 had no effect on
cell viability and proliferation of a panel of six breast cancer cell
lines with different genetic backgrounds. In contrast, Z-LLNle-
CHO could cause cell death even at concentrations that did
not completely inhibit γ-secretase activity. Therefore, we con-
clude that the cell killing effect of Z-LLNle-CHO on breast can-
cer cells is not mediated by γ-secretase inhibition.
We next measured the proteasome inhibition potential of Z-
LLNle-CHO. In contrast to two previous reports that Z-LLNle-
CHO at concentrations that inhibited cell growth did not sig-
nificantly inhibit proteasome activity (see supplemental materi-
als in [15,26]), we found that it could inhibit proteasome
activity by about 50% in intact cells even at a concentration
that did not show significant cytotoxicity in two cell lines
tested. Our result is consistent with a recent study that was
published during the revision of this manuscript [27]. The new
study showed that Z-LLNle-CHO at about 0.3 μM (calculated
by us based on scale) inhibited proteasome activity by 80%
and slowed cell growth by 20% in MCF-7 cells. As the
approach the new study used to measure proteasome activity
is different from ours, the extent of proteasome activity inhibi-
tion cannot be compared between their data and ours. How-
ever, both studies show that Z-LLNle-CHO could significantly
inhibit proteasome activity at concentrations that showed
dose-dependent cytotoxicity. The previous two studies used
the same method to measure proteasome activity as the latest
study but differed from ours. Therefore, it is easy to explain the
discrepancy between their data and ours but we cannot
explain the discrepancy between their data and the latest
study.
Furthermore, we found that the relative cellular sensitivity of six
breast cancer cell lines to Z-LLNle-CHO was the same as that
to three widely used but structurally unrelated proteasome
inhibitors and was also consistent with a previous study [23].
This consistency strongly suggests that the cell killing effect of
Z-LLNle-CHO is due to its proteasome inhibitory function.
Most convincingly, we found that the cytotoxic effect of Z-
LLNle-CHO could be reversed by a specific antioxidant that
blocked its proteasome inhibitory activity. Finally, we tested
but did not find any additive effect of the combination of a spe-
cific γ-secretase inhibitor and a specific proteasome inhibitor
on breast cancer cell growth. Therefore, we conclude that the
cytotoxicity of Z-LLNle-CHO to breast cancer cells is medi-
ated by proteasome inhibition.
We noticed that edaravone treatment also partially rescued γ-
secretase activity from Z-LLNle-CHO-induced inhibition. How-
ever, because inhibition of γ-secretase alone or in combination
with proteasome inhibition had no effect on cell survival/prolif-
eration or cellular response to proteasome inhibition, we do
not consider partially restored γ-secretase activity as a major
contributor to the reversion of the cytotoxicity induced by Z-
LLNle-CHO. Likewise, although edaravone has been reported
to protect cells from apoptosis by acting as an antioxidant
[28,29], we do not think its free radical scavenging activity is
a major contributor because it had no effect on bortezomib-
induced cytotoxicity. Therefore, its ability to restore proteas-
ome activity through unknown mechanism(s) most likely
accounts for the reversion of the cytotoxicity of Z-LLNle-CHO.
Both previous studies used transient transfection of N1ICD to
rescue the cell death induced by Z-LLNle-CHO treatment and
argued that the reversion of the phenotype by N1ICD transfec-
tion indicated that Z-LLNle-CHO induced cell death through
inhibiting Notch signaling pathway [15,16]. However, tran-
sient overexpression of N1ICD has been reported to inhibit
wild-type p53-induced apoptosis in immortalized epidermal
cells [30], to inhibit dexamethasone, etoposide, or Fas-ligand-
induced apotosis in mature T-cells [31], and to protect H460
(lung cancer), HepG2 (liver cancer), and HT1080 (fibrosar-
coma) from several chemotherapy drugs [32]. Therefore, an
alternative interpretation of the data from the two previous
studies is that N1ICD over-expression provided pro-survival
signals that antagonize the pro-apoptotic effects of Z-LLNle-
CHO.
It is worthy noting that many of the effects of Z-LLNle-CHO
reported in previous studies, including G2/M arrest and regu-
lation of apoptosis-related protein, are consistent with the
reported effects of other proteasome inhibitors [33-37]. In
addition, similar to the additive effects of 4-OH-TAM and Z-
LLNle-CHO on the inhibition of T47D:A18 cells growth [15],
additive or even synergistic effects have also been reported
between tamoxifen and bortezomib in some but not all ER-pos-
itive breast cancer cell lines tested [38,39]. Although the sim-
Figure 6
No additive effect from the combination of γ-secretase inhibition and  proteasome inhibiton No additive effect from the combination of γ-secretase inhibition 
and proteasome inhibiton. Cells were exposed to increasing concen-
trations of lactacystin with or without 5 μM of DAPT for 72 hours and 
cell growth was measured by MTS assay. Results represent the mean 
± standard deviation of three independent experiments.Breast Cancer Research    Vol 11 No 4    Han et al.
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ilarities between the biological effects of Z-LLNle-CHO and
those of other proteasome inhibitors do not necessarily mean
that they function the same, our finding that Z-LLNle-CHO
inhibits breast cancer cell growth as a proteasome inhibitor
can explain the data produced with the use of Z-LLNle-CHO
in previous studies.
It should be pointed out that although the latest study by Rasul
and colleagues found that Z-LLNle-CHO has proteasome
inhibitory function at concentrations that showed dose-
dependent cytotoxicity [27], the authors did not consider its
proteasome inhibitory activity as the major contributor to its
cell killing effects because the cytotoxicity of Z-LLNle-CHO
and MG132 was 'markedly different', although their proteas-
ome inhibition potential was similar. However, by careful anal-
ysis of their data, we found that the proteasome inhibition
potentials of Z-LLNle-CHO and MG132 differed by more than
two-fold, not less than the difference in cytotoxicity, within the
range of concentrations that Z-LLNle-CHO and MG132
showed 'markedly different' cytotoxicity (below 0.6 μM). Most
importantly, Z-LLNle-CHO at 0.75 μM in their study slowed
MCF-7 cell growth by 80%, but only inhibited γ-secretase
activity by 25%. Meanwhile, it inhibited proteasome activity by
80%. Therefore, their data is more consistent with our conclu-
sion that the cytotoxicity of Z-LLNle-CHO was not due to γ-
secretase inhibition, but due to proteasome inhibition.
The observation that both Z-LLNle-CHO and MG132 at given
concentrations inhibited proteasome activities to comparable
levels in MCF-7 and MDA-MB-231 cells, but showed different
cytotoxicity, is not surprising because this has also been
observed for bortezomib [23]. The reduced sensitivity of ER-
positive MCF-7 cells may be a consequence of pro-survival
signal provided by the ER signaling pathway in these ER-pos-
itive breast cancer cells. This hypothesis is consistent with the
observed additive or even synergistic effect between
tamoxifen and Z-LLNle-CHO or bortezomib. However, this
requires further investigation. Regardless of the mechanisms,
our results, together with the previous reports, suggest that
the future clinical trials testing the effectiveness of proteasome
inhibitors in treating breast cancer should take the ER status
into consideration when enrolling patients.
The observation that two specific GSIs, DAPT and L-685,458,
had no effect on the survival and proliferation of breast cancer
cells does not eliminate the potential use of GSIs or other
approaches to block Notch signaling for breast cancer treat-
ment. The results presented here were obtained from in vitro
cell culture experiments. The effects of GSIs on the tumors
grown in vivo, where the Notch signaling might be more active
due to enhanced ligand-receptor interaction, could be differ-
ent and need further investigation. Alternatively, these drugs
might block the signaling pathway of some as yet unidentified
substrate(s) which antagonizes the effect of reduced Notch1
signaling on breast cancer cell survival and proliferation. There
are at least a dozen known γ-secretase substrates and most of
the available GSIs have no preference for specific substrates.
Rather than laboriously testing all potential candidates that
antagonize Notch1, it might be better to develop substrate-
specific GSIs. To this end, it is encouraging to note that com-
pounds that can preferentially modulate γ-secretase activity
against Aβ42 over Notch have recently been reported [40].
These compounds target the substrate (Aβ42) rather than the
γ-secretase active site itself. In principle, it should also be pos-
sible to find drugs that target individual Notch homologs. Alter-
natively, it might be useful to develop neutralizing antibody
against individual Notch homologs just as the trastuzumab tar-
gets HER2/neu.
Furthermore, the results of this study do not diminish the
potential use of Z-LLNle-CHO for breast cancer treatment. In
fact, we believe that clarifying its role as a proteasome and γ-
secretase dual inhibitor will help to direct its potential develop-
ment for clinical use. However, we do caution that results
obtained using Z-LLNle-CHO as the sole GSI to study the bio-
logical outcomes of blocking Notch signaling [41-43] should
be interpreted cautiously or reproduced using more specific
GSIs.
Conclusions
The present study demonstrated that the cytotoxicity of Z-
LLNle-CHO toward breast cancer cells was not mediated by
γ-secretase inhibiton as reported previously, but by proteas-
ome inhibition. This clarification might help its potential devel-
opment as a chemotherapeutic agent. The results presented
also call for careful interpretation of data produced with using
Z-LLNle-CHO as the sole γ-secretase inhibitor.
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